SCHEMBL5452084

SCHEMBL5452084

NC(=O)c1c(NC(=O)C2CC2CN2CCOCC2)sc2c1CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
HSD17B10 Q99714 2/20 0.55
KDM4E B2RXH2 2/20 0.55
ALOX15 P16050 1/20 0.55
CFTR P13569 1/20 0.49
CNR2 P34972 10/20 0.46
HPGD P15428 3/20 0.45
TSHR P16473 2/20 0.45
MAPK10 P53779 1/20 0.45
MDM2 Q00987 1/20 0.45
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CNR1 P21554 4/20 0.44
PTPRC P08575 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPRB P23467 1/20 0.44
PTPRE P23469 1/20 0.44
FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460250 0.91 CFTR (0.49) ALDH1A1HSD17B10KDM4EALOX15CFTR
SCHEMBL5450939 0.85 CFTR (0.54) ALDH1A1HSD17B10KDM4EALOX15CFTR
SCHEMBL14361079 0.84 CFTR (0.56) ALDH1A1HSD17B10KDM4ECFTRCNR2
SCHEMBL5460372 0.82 CNR2 (0.54) ALDH1A1HSD17B10KDM4EALOX15CFTR
SCHEMBL5453253 0.82 CFTR (0.53) ALDH1A1HSD17B10KDM4EALOX15CFTR
SCHEMBL5466126 0.80 CFTR (0.57) ALDH1A1HSD17B10KDM4ECFTRCNR2
SCHEMBL5460380 0.80 CFTR (0.60) ALDH1A1HSD17B10KDM4ECFTRCNR2
SCHEMBL5449705 0.79 CFTR (0.51) ALDH1A1HSD17B10KDM4ECFTRCNR2
SCHEMBL5455084 0.78 CFTR (0.47) ALDH1A1HSD17B10KDM4EALOX15CFTR
SCHEMBL5457693 0.77 KMT2A (0.60) ALDH1A1HSD17B10KDM4EALOX15CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ALDH1A1 1153/4885HSD17B10 635/4885KDM4E 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.